Researchers demonstrated atomically precise, de novo antibody design using RFdiffusion and validated binding poses with cryo‑EM, marking a step change in computational biologics design published in Nature. The work shows AI can generate full‑length antibody scaffolds that bind specified epitopes with atomic accuracy, confirmed across viral and toxin targets. Nobel laureate David Baker and colleagues stress the advance but caution that design‑to‑clinic pipelines and downstream optimization remain work in progress. The result accelerates efforts to shorten antibody discovery timelines and could reshape how biotechs approach target engagement and lead selection.